LogicBio Therapeutics (NASDAQ:LOGC) issued its quarterly earnings data on Tuesday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.04), Fidelity Earnings reports.
LOGC traded down $0.32 during trading hours on Wednesday, hitting $8.48. 6,569 shares of the company’s stock were exchanged, compared to its average volume of 21,328. LogicBio Therapeutics has a 12-month low of $6.70 and a 12-month high of $20.07. The stock’s 50 day moving average price is $12.11. The stock has a market cap of $221.57 million and a price-to-earnings ratio of -2.79.
Several equities research analysts recently weighed in on LOGC shares. Chardan Capital reaffirmed a “buy” rating on shares of LogicBio Therapeutics in a research note on Monday, July 29th. Roth Capital started coverage on shares of LogicBio Therapeutics in a research note on Wednesday, May 1st. They set a “buy” rating and a $26.00 target price on the stock. ValuEngine raised shares of LogicBio Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research raised shares of LogicBio Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $24.00.
About LogicBio Therapeutics
LogicBio Therapeutics, Inc, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.
Recommended Story: Hedge Funds – How They Work For Investors
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.